SEC Filing Summary

This filing corrects a previous report regarding a grant of 94,500 shares. Upon the vesting of the first semi-annual installment, the accurate number of shares is reported. The transaction involves 47,700 Restricted Stock Units (RSUs) granted to Joshua A. Kazam, a director at Allogene Therapeutics, Inc. Each RSU represents a contingent right to receive one share of common stock or its cash equivalent. These RSUs vest in two equal semi-annual installments over one year, contingent on continued service. The filing also notes the acquisition of 47,700 shares of Common Stock, with a post-transaction holding of 350,763 shares.